New Aytu Advisory Board Working to Advance AR101 for vEDS

New Aytu Advisory Board Working to Advance AR101 for vEDS

305920

New Aytu Advisory Board Working to Advance AR101 for vEDS

Aytu BioPharma has formed its new scientific advisory board, which will work toward advancing the global development of AR101 (enzastaurin), an antitumor agent with the potential to treat vascular Ehlers–Danlos syndrome (vEDS). There currently are no approved treatments for vEDS, characterized by thin, translucent skin that is easily bruised, and fragile arteries, muscles, and internal organs. The company is planning a pivotal clinical trial called PREVEnt  — Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome —…

You must be logged in to read/download the full post.